An Adenoma That Isn't Doing Anything Yet: Surgery or Watching, in a Patient With No Symptoms
A single patient, an 18mm nonfunctioning pituitary adenoma found incidentally, with normal vision, normal hormones, and no complaints. The disagreement is whether to operate before anything goes wrong, or watch and wait for a reason to.
T.A., a 61-year-old man, retired last year from thirty-four years as a long-haul truck driver and has spent most of that year, by his own cheerful account, "finally sleeping in a bed that doesn't move." A head CT obtained after a minor fender-bender, ordered to rule out intracranial injury, incidentally showed a sellar mass; follow-up MRI confirmed an 18mm pituitary macroadenoma with superior extension abutting but not compressing the optic chiasm. Formal visual field testing is entirely normal, and a full hormonal panel — prolactin, IGF-1, morning cortisol, free T4, TSH, testosterone, LH/FSH — is unremarkable, consistent with a nonfunctioning adenoma rather than a hormone-secreting one. He has no headaches, no visual complaints he'd noticed on his own, and no other symptoms; the entire finding exists because of a fender-bender that otherwise left him unhurt.
The natural-history data on lesions like his is genuinely mixed rather than reassuring across the board. Longitudinal surveillance series following untreated nonfunctioning macroadenomas have found tumor growth in a substantial minority to a majority of patients over five-to-eight-year follow-up, with growth rates varying considerably by initial size and internal composition — cystic and mixed-signal lesions tend to grow faster and less predictably than solid ones, and his own MRI shows a solid, homogeneous lesion, the more slowly progressive pattern within that literature. Visual compromise specifically, though, develops in only a minority of patients under active surveillance with scheduled re-imaging, precisely because growth is caught and surgery offered before chiasm compression becomes symptomatic — the surveillance model's entire premise is that watching closely enough makes elective, not emergent, surgery the actual fallback, not a foregone one. His case sits at a genuinely favorable point within that literature: a solid lesion already abutting rather than displacing the chiasm is the profile surveillance series describe as most reliably caught before compression develops, not the more unpredictable cystic pattern that has driven some centers toward earlier surgery regardless of symptoms.
A tumor with no symptoms yet — the question is what "yet" is worth
I'd offer elective surgery now rather than wait for growth. He's already abutting the chiasm with no room to spare, and once compression begins, surgery shifts from a planned, elective procedure with excellent outcomes to a more urgent one on a nerve structure that's already under some pressure — the surgical risk profile is genuinely better before symptoms start than after.
I'd hold off and enroll him in active surveillance instead. His lesion is solid and homogeneous, the pattern the natural-history literature consistently associates with slower, more predictable growth, and his visual fields are normal today — the surveillance model isn't "wait and hope," it's scheduled re-imaging specifically designed to catch growth before it reaches the chiasm, at which point elective surgery is still on the table, not foreclosed.
The real cost of surgery now isn't trivial either — even excellent outcomes carry a real risk of new hypopituitarism requiring lifelong hormone replacement, a cost he'd be accepting today for a tumor that hasn't shown it needs treating.
You're right that his lesion's composition favors the slower-growth pattern, and I'll concede surveillance is defensible here specifically because of that — a cystic or mixed lesion this close to the chiasm would change my answer. What I'd insist on is the surveillance protocol itself being concrete: repeat MRI at 6 months, not the standard annual interval, given how little room he has before any growth becomes compression, then annually if that first scan is stable.
Agreed: active surveillance with MRI at 6 months rather than the standard annual interval, given his minimal margin from the chiasm, then annually if that scan is stable; formal visual fields repeated at each imaging visit rather than only on symptom report. Both physicians converged once the lesion's solid composition and the tightened imaging interval were both on the table explicitly.
The neurosurgeon's initial position was for surgery now; the concession that composition genuinely changes the calculus, paired with a shorter surveillance interval than default, resolved the disagreement without either side simply deferring to the other.